Incyte (INCY) Competitors $72.75 -0.49 (-0.67%) (As of 11:33 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INCY vs. ALNY, BIIB, UTHR, NBIX, BMRN, EXAS, EXEL, RGEN, MDGL, and HALOShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry. Incyte vs. Alnylam Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences BioMarin Pharmaceutical Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings, community ranking and profitability. Is ALNY or INCY more profitable? Incyte has a net margin of 0.80% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Incyte's return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% Incyte 0.80%-0.63%-0.45% Does the MarketBeat Community believe in ALNY or INCY? Incyte received 88 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.14% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.77% of users gave Incyte an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes113376.14% Underperform Votes35523.86% IncyteOutperform Votes122172.77% Underperform Votes45727.23% Do institutionals & insiders have more ownership in ALNY or INCY? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 17.6% of Incyte shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk & volatility, ALNY or INCY? Alnylam Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Do analysts recommend ALNY or INCY? Alnylam Pharmaceuticals currently has a consensus price target of $298.09, indicating a potential upside of 17.82%. Incyte has a consensus price target of $77.16, indicating a potential upside of 5.35%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 0 Strong Buy rating(s) 2.71Incyte 1 Sell rating(s) 11 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.38 Which has better valuation & earnings, ALNY or INCY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$1.83B17.85-$440.24M-$2.62-96.57Incyte$3.70B3.82$597.60M$0.14523.18 Does the media refer more to ALNY or INCY? In the previous week, Alnylam Pharmaceuticals had 7 more articles in the media than Incyte. MarketBeat recorded 30 mentions for Alnylam Pharmaceuticals and 23 mentions for Incyte. Incyte's average media sentiment score of 0.97 beat Alnylam Pharmaceuticals' score of 0.70 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 16 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryIncyte beats Alnylam Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.11B$4.57B$5.36B$8.94BDividend YieldN/A1.59%5.33%4.05%P/E Ratio523.1858.65117.6718.00Price / Sales3.8264.581,424.20155.72Price / Cash30.6324.3542.8038.60Price / Book4.453.457.356.66Net Income$597.60M$139.66M$118.46M$224.93M7 Day Performance-2.09%4.99%3.40%2.50%1 Month Performance-3.80%21.79%2.49%10.24%1 Year Performance35.58%23.18%36.17%30.14% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.6683 of 5 stars$72.75-0.7%$77.16+6.1%+35.6%$14.02B$3.70B519.682,524Short Interest ↓ALNYAlnylam Pharmaceuticals4.2156 of 5 stars$253.94+0.3%$298.09+17.4%+47.6%$32.75B$1.83B-97.312,100Upcoming EarningsBIIBBiogen4.9564 of 5 stars$160.63+0.5%$257.20+60.1%-30.0%$23.41B$9.84B14.517,570Short Interest ↓Positive NewsUTHRUnited Therapeutics4.6343 of 5 stars$370.62+0.0%$370.86+0.1%+53.7%$16.55B$2.33B16.271,168Positive NewsNBIXNeurocrine Biosciences4.9227 of 5 stars$126.75+0.1%$163.91+29.3%+7.5%$12.83B$1.89B33.981,400Positive NewsBMRNBioMarin Pharmaceutical4.993 of 5 stars$65.73-0.5%$94.20+43.3%-29.6%$12.53B$2.42B39.543,401Positive NewsEXASExact Sciences4.5416 of 5 stars$60.74-2.2%$75.29+24.0%-8.0%$11.24B$2.50B-53.066,600EXELExelixis4.827 of 5 stars$35.60-2.4%$31.44-11.7%+62.2%$10.17B$2.08B23.291,310Insider TradeShort Interest ↓RGENRepligen4.62 of 5 stars$151.85+0.9%$190.25+25.3%-8.8%$8.51B$638.76M-406.851,783Positive NewsMDGLMadrigal Pharmaceuticals4.1518 of 5 stars$320.00-2.5%$347.33+8.5%+49.5%$6.98BN/A-13.0990Positive NewsHALOHalozyme Therapeutics4.986 of 5 stars$48.39+0.4%$61.11+26.3%+22.4%$6.16B$829.25M15.96390 Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Exelixis Competitors Repligen Competitors Madrigal Pharmaceuticals Competitors Halozyme Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INCY) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
